Allena Competitors

Delisted . USA . 
Stock . Allena Pharmaceuticals
ALNAQDelisted Stock  USD 0  0.00  0.00%   
Allena Pharmaceuticals competes with Cellectis; as well as few others. The company classifies itself under Healthcare sector and is part of Biotechnology industry. Analyzing Allena Pharmaceuticals competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Allena Pharmaceuticals to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Allena Pharmaceuticals competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.0000.00
Details
Intrinsic
Valuation
LowRealHigh
0.0000.00
Details
Naive
Forecast
LowNextHigh
0.010.010.01
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
-0.00290.010.02
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Allena Pharmaceuticals. Your research has to be compared to or analyzed against Allena Pharmaceuticals' peers to derive any actionable benefits. When done correctly, Allena Pharmaceuticals' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Allena Pharmaceuticals.

Allena Pharmaceuticals Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Allena Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Allena and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Allena Pharmaceuticals does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
BIOAF
+ 1.0
APTCF
TCDAQ
+ 0.48
SCPS
SCPS
+ 0.46
CHNXF
BITRF
+ 0.3
CHNXF
TCDAQ
+ 0.28
MRZM
TCDAQ
+ 0.23
CHNXF
  
High negative correlations   
TCDAQ
- 0.79
MGTA
MGTA
- 0.53
SCPS
MRZM
- 0.39
MGTA
TCDAQ
- 0.32
BITRF
MGTA
- 0.29
CHNXF
SCPS
- 0.18
BITRF

Risk-Adjusted Indicators

There is a big difference between Allena Pink Sheet performing well and Allena Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Allena Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
APTCF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
CMVLF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
CHNXF  3.06 (1.72) 0.00 (3.61) 0.00 
 0.00 
 0.00 
(5.56)
 48.28 
BITRF  3.09 (1.13) 0.00 (0.70) 0.00 
 0.00 
 1.34 
(5.84)
 62.53 
BIOAF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
CDAKQ  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
SCPS  12.77  0.26  0.01  4.68  17.13 
(16.39)
 35.42 
(24.69)
 94.02 
MGTA  2.62  0.04  0.00  0.19  3.40 
(3.33)
 5.88 
(4.29)
 16.99 
MRZM  9.89  3.01  0.07 (0.72) 9.63 
(56.94)
 50.00 
(20.00)
 128.57 
TCDAQ  8.00 (3.21) 0.00 (4.60) 0.00 
 0.00 
 13.33 
(17.07)
 76.06 
All Fundamental Data

Allena Pharmaceuticals Competitive Analysis

The better you understand Allena Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Allena Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Allena Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
ALNAQ APTCF CMVLF CHNXF BITRF BIOAF SCPS MGTA MRZM TCDAQ
 0.00 
 0 
Allena
 0.00 
 0.0002 
Advanced
 0.00 
 2.54 
Cellectis
 0.00 
 0.01 
ChitogenX
 0.00 
 0.01 
Biotron
 0.00 
 0.0001 
BiOasis
 0.00 
 0.10 
Scopus
 3.80 
 0.82 
Magenta
 25.00 
 0.05 
Marizyme
 21.74 
 0.03 
Tricida
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Very steady
Out of control
Out of control
Very steady
Very steady
Very steady
Out of control
Very steady
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
OK
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Below Average
Low
Very High
Below Average
Very High
Dangerous
Dangerous
Below Average
Dangerous
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Strong Sell
Strong Hold
Strong Sell
Strong Sell
Strong Sell
Not Rated
Not Rated
Strong Sell
Not Rated
Current Ratio
1.58
0.55
3.17
1.26
2.35
0.38
0.31
10.22
1.74
N/A
Net Asset
34.76 M
636.41 K
382.08 M
1.12 M
1.91 M
2.27 M
8.19 M
146.65 M
66 M
168.51 M
Profit Margin
N/A
N/A
N/A
N/A
-1.78
N/A
N/A
N/A
N/A
N/A
EBITDA
(47.29 M)
631.22 K
(103.2 M)
(3.72 M)
(2.73 M)
(3.54 M)
(26.18 M)
(78.98 M)
(10.83 M)
(158.52 M)
Current Valuation
(181.84 K)
660.53 K
82.79 M
12.49 M
15.31 M
6 M
1.18 M
(32.66 M)
17.35 M
N/A
Price To Book
0.3
4.92
0.79
N/A
23.61
53.47
2.42
0.54
0.37
N/A
Operating Margin
N/A
N/A
-6.01
N/A
-1.78
-11.41
N/A
N/A
-180.85
N/A
Retained Earnings
N/A
N/A
(206 M)
N/A
(37 M)
(18.69 M)
N/A
(402.03 M)
N/A
N/A
Current Asset
N/A
N/A
297 M
N/A
3 M
874 K
N/A
33.34 M
N/A
N/A
Beta
1.32
1.55
2.0
0.43
-1.2
0.39
1.16
2.12
0.36
N/A
Number Of Employees
12
11
294
6
10
23
9
67
11
57
Shares Outstanding
122.08 M
41.13 M
55.59 M
51.04 M
901.94 M
79.41 M
21.09 M
60.66 M
10.13 M
N/A
Cash Flow From Operations
(45.68 M)
(693.58 K)
(104.56 M)
(3.22 M)
(2.44 M)
(3.64 M)
(11.42 M)
(67.09 M)
(5.79 M)
(140.06 M)
Total Debt
5.28 M
227.41 K
18.77 M
4.78 M
77.24 K
401.76 K
2.54 M
29.96 M
495.32 K
127.51 M
Return On Equity
-5.41
N/A
-0.56
N/A
-1.12
N/A
-15.6
-0.65
-0.5
N/A
Z Score
-3.3
6.0
4.2
-8.7
N/A
-11.5
-9.9
-3.88
6.0
N/A
Return On Asset
-1.07
-1.07
-0.24
-2.92
-0.56
-0.81
-4.61
-0.29
-0.15
N/A
Number Of Shares Shorted
10.34 M
N/A
N/A
N/A
N/A
N/A
23.77 K
383.03 K
N/A
N/A
Book Value Per Share
0.035
0.015
3.0
-0.15
0.002
-0.034
-0.26
1.24
1.0
N/A
Current Liabilities
N/A
N/A
58 M
N/A
N/A
437 K
N/A
3.39 M
N/A
N/A
Total Asset
34.76 M
636.41 K
382.08 M
1.12 M
1.91 M
2.27 M
8.19 M
146.65 M
66 M
168.51 M
Debt To Equity
1.41
4.65
0.52
N/A
0.07
0.31
0.61
0.25
0.066
N/A
Short Ratio
0.62
N/A
N/A
N/A
N/A
N/A
0.22
1.38
N/A
N/A
Target Price
4.0
N/A
N/A
N/A
N/A
0.58
12.0
1.0
N/A
N/A
Shares Owned By Institutions
0.26
N/A
9.8
N/A
N/A
N/A
2.15
62.63
N/A
N/A
Market Capitalization
244.17 K
2.47 M
131.39 M
9.86 M
18.67 M
2.13 M
2.17 M
45.14 M
5.07 M
N/A
Price To Earning
N/A
2.98
-13.64
N/A
-3.04
13.82
N/A
-1.63
N/A
N/A
Price To Sales
N/A
N/A
4.79
N/A
11.17
26.52
N/A
N/A
133.06
N/A
Net Income
(48.66 M)
759.62 K
(114.2 M)
(4.92 M)
(2.78 M)
(2.96 M)
(26.95 M)
(76.46 M)
(11 M)
(176.57 M)
Earnings Per Share
N/A
0.02
-2.95
N/A
-0.003
-0.031
-1.51
-1.11
-0.38
N/A
Shares Owned By Insiders
0.92
10.53
N/A
17.44
14.13
2.05
50.66
2.23
2.04
N/A
Revenue
N/A
N/A
57.29 M
N/A
1.56 M
37.73 K
N/A
N/A
210.28 K
N/A
Working Capital
N/A
N/A
239 M
N/A
3 M
437 K
N/A
101.05 M
N/A
N/A
Cash And Equivalents
6.59 M
761.6 K
153.13 M
2.19 M
1.74 M
764.97 K
1.16 M
128.28 M
2.04 M
N/A
Cash Per Share
0.05
0.02
3.37
0.04
N/A
0.01
0.05
2.13
0.05
N/A
Gross Profit
N/A
(1.71 K)
34.18 M
N/A
1.56 M
(1.15 M)
N/A
N/A
129.93 K
N/A
Day Typical Price
0.002
2.0E-4
2.54
0.0051
0.0125
1.0E-4
0.1
0.81
0.05
0.027
Accumulation Distribution
N/A
N/A
N/A
N/A
N/A
N/A
0.0909
0.0482
N/A
0.23
Market Facilitation Index
N/A
N/A
N/A
N/A
N/A
N/A
0.01
0.04
N/A
0.007
Daily Balance Of Power
0.0
0.0
0.0
0.0
0.0
0.0
N/A
0.75
9.2 T
0.7143
Period Momentum Indicator
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.03
0.01
0.005
Rate Of Daily Change
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.04
1.25
1.22
Day Median Price
0.002
2.0E-4
2.54
0.0051
0.0125
1.0E-4
0.11
0.81
0.05
0.0265
Price Action Indicator
N/A
N/A
N/A
N/A
N/A
N/A
(0.01)
0.025
0.005
0.004
Coefficient Of Variation
2158.05
N/A
N/A
(470.07)
(996.94)
N/A
7178.48
2966.12
821.34
(356.28)
Mean Deviation
15.45
N/A
N/A
3.06
3.09
N/A
12.77
2.62
9.89
8.0
Jensen Alpha
1.61
N/A
N/A
(1.72)
(1.13)
N/A
0.2552
0.0381
3.01
(3.21)
Total Risk Alpha
(3.42)
N/A
N/A
(2.95)
(2.52)
N/A
(3.00)
(0.50)
(0.96)
(4.97)
Sortino Ratio
0.0417
N/A
N/A
N/A
N/A
N/A
0.0062
(0)
0.0726
N/A
Downside Variance
790.01
N/A
N/A
N/A
N/A
N/A
479.22
17.78
1125.49
N/A
Standard Deviation
28.27
N/A
N/A
7.75
9.39
N/A
19.55
3.69
21.13
11.08
Kurtosis
6.03
N/A
N/A
28.01
31.69
N/A
2.41
3.46
9.65
3.74
Potential Upside
57.14
N/A
N/A
N/A
1.34
N/A
35.42
5.88
50.0
13.33
Treynor Ratio
(0.53)
N/A
N/A
(3.61)
(0.70)
N/A
4.68
0.1912
(0.72)
(4.60)
Maximum Drawdown
150.0
N/A
N/A
48.28
62.53
N/A
94.02
16.99
128.57
76.06
Variance
799.2
N/A
N/A
60.08
88.26
N/A
382.24
13.63
446.31
122.82
Market Risk Adjusted Performance
(0.52)
N/A
N/A
(3.60)
(0.69)
N/A
4.69
0.2012
(0.71)
(4.59)
Risk Adjusted Performance
0.0452
N/A
N/A
(0.15)
(0.07)
N/A
0.0203
0.0337
0.1027
(0.21)
Skewness
1.13
N/A
N/A
(5.26)
(3.81)
N/A
0.2581
(0.42)
2.42
0.068
Semi Deviation
18.59
N/A
N/A
N/A
N/A
N/A
17.13
3.4
9.63
N/A
Information Ratio
0.0415
N/A
N/A
(0.23)
(0.11)
N/A
0.0069
(0)
0.1152
(0.29)
Value At Risk
(38.46)
N/A
N/A
(5.56)
(5.84)
N/A
(24.69)
(4.29)
(20.00)
(17.07)
Expected Short fall
(36.08)
N/A
N/A
N/A
N/A
N/A
(16.39)
(3.33)
(56.94)
N/A
Downside Deviation
28.11
N/A
N/A
N/A
N/A
N/A
21.89
4.22
33.55
N/A
Semi Variance
345.49
N/A
N/A
N/A
N/A
N/A
293.43
11.57
92.76
N/A

Allena Pharmaceuticals Competition Performance Charts

Five steps to successful analysis of Allena Pharmaceuticals Competition

Allena Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Allena Pharmaceuticals in relation to its competition. Allena Pharmaceuticals' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Allena Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Allena Pharmaceuticals' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Allena Pharmaceuticals, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Allena Pharmaceuticals position

In addition to having Allena Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Tech Funds Thematic Idea Now

Tech Funds
Tech Funds Theme
Funds or Etfs that invest in companies involved in research, development, testing, or distribution of technologically based goods and services. The Tech Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Tech Funds Theme or any other thematic opportunities.
View All  Next Launch
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Other Consideration for investing in Allena Pink Sheet

If you are still planning to invest in Allena Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Allena Pharmaceuticals' history and understand the potential risks before investing.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY